Cerebral palsy is a group of disorders that affect a person’s ability to move and maintain balance and posture. Cerebral palsy is the most common motor disability in childhood. Cerebral palsy is caused by abnormal brain development or damage to the developing brain that affects a person’s ability to control his or her muscles.
Patients suffering from cerebral palsy require lifelong care with a medical care team. Although there is no cure for cerebral palsy there are various treatments like medications, therapies, surgical procedures and other treatments. Medications include muscle or nerve injections, and oral muscle relaxants. Major therapies include physical therapies, occupational therapies, speech and language therapies and recreational therapies.
The factors that drive the growth of the global cerebral palsy treatment market include upsurge in the prevalence of cerebral palsy, rising focus on the healthcare technological advancements coupled with growing availability of newer cerebral palsy drugs, increasing research and development proficiencies, government initiatives to promote the awareness and increasing reliance on medications are the major factors prevailing the growth of the global cerebral palsy treatment market.
However, high costs associated with medications is expected to create hindrances for the growth of the cerebral palsy treatment market. Moreover, Side effects associated with the medications such as drowsiness, depression, headaches, lethargy, confusion, and dizziness and lack of awareness in the backward and underdeveloped economies are causing hurdles in the cerebral palsy treatment market.
Various initiatives have been taken by the government to encourage the regulatory affairs in getting approvals for novel drugs, and insurance policies which are creating lucrative opportunities in the cerebral palsy treatment market.
The report segments the market based on drug type, disease type, distribution channel, and region. Based on drug type, it is classified into anticholinergics, anticonvulsants, antidepressants, and others. Based on disease type, it is classified into spastic cerebral palsy, dyskinetic cerebral palsy, ataxic cerebral palsy, and mixed cerebral palsy. Based on distribution channel, the market is divided into hospital pharmacies, retail stores and pharmacies, and online providers. Based on the region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Region wise, this market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America accounted for the largest market share in the cerebral palsy treatment market in 2020, and is expected to retain its dominance throughout the forecast period. This is primarily attributed to significant rise in investments as well as partnerships and collaborations.
Business expansions is the key strategy adopted by market players. The report provides a comprehensive analysis of the key players that operate in the global cerebral palsy treatment market. The key companies profiled in the report include Merz Pharmaceuticals, LLC., Pfizer Inc., Teva Pharmaceuticals, Bayer AG, Johnson & Johnson, GlaxoSmithKline plc., Novartis, AbbVie Inc., Par Pharmaceutical, Allergan plc., Lannett Company, Inc.
KEY BENEFITS FOR STAKEHOLDERS
- The report provides in-depth analysis of the global Cerebral Palsy Treatment market size along with the current trends and future estimations to elucidate the imminent investment pockets
- It offers market analysis from 2021 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market
- A comprehensive analysis on region assists to understand the regional market and facilitate the strategic business planning and determine prevailing opportunities
- The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global Cerebral Palsy Treatment market growth
KEY MARKET SEGMENTS
By Drug Type
- Anticholinergics
- Anticonvulsants
- Antidepressants
- Other
By Disease Type
- Spastic Cerebral Palsy
- Dyskinetic Cerebral Palsy
- Ataxic Cerebral Palsy
- Mixed Cerebral Palsy
By Distribution Channel
- Hospital Pharmacies
- Retail stores and Pharmacy
- Online Providers
By Region
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
List of key players profiled in the report:
- Merz Pharmaceuticals, LLC
- Pfizer Inc
- Teva Pharmaceuticals
- Bayer AG
- Johnson & Johnson
- GlaxoSmithKline plc
- Novartis
- AbbVie Inc
- Par Pharmaceutical
- Allergan plc
- Lannett Company, Inc
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
Executive Summary
According to a new report titled, “Cerebral Palsy Treatment Market by drug type, disease type, distribution channel and region: Global Opportunity Analysis and Industry Forecast, 2021–2030,” The global cerebral palsy treatment market size was valued at $3166.82 million in 2020, and is projected to reach $4,365.01 million by 2030, registering a CAGR of 3.3% from 2021 to 2030.Cerebral palsy is a problem that affects muscle tone, movement, and coordination. It happens when the brain cannot properly send messages to muscles about how to move in smooth or well-coordinated way. It can also affect other body functions that involve motor skills and muscles, such as breathing, bladder and bowel control, eating, and talking.
Rapid growth of the cerebral palsy treatment market is attributed to increase incidences of cerebral palsy, coupled with rise in awareness among parents regarding complications of cerebral palsy and availability of various treatments options. The market for cerebral palsy treatment has witnessed tremendous growth in the recent years, owing to surge in demand for the medication.
Rise in incidences of cerebral palsy can be attributed to multiple factors, such as premature birth or low weight at the time of birth, multiple child births, and incidences of infectious diseases at the time of pregnancy. Further, health conditions of mother may also lead to cerebral palsy in the child through conditions such as thyroid, seizures, and intellectual disability. Rapid growth of the cerebral palsy treatment market can be attributed to increase in incidences of cerebral palsy, coupled with rise in awareness among parents regarding complications of cerebral palsy and availability of various treatments options in the market. However, side effects associated with drugs are expected to limit growth of the cerebral palsy treatment market in the next few years.
Increase in number of approvals and product launches among key players and biopharmaceutical companies and technological advancements in cerebral palsy treatment fuel growth of the market.
The cerebral palsy treatment market is segmented on the basis of drug type, disease type, distribution channel, and region. On the basis of drug type, the market is divided into anticholinergics, anticonvulsants, antidepressants, and others. The anticonvulsants segment dominated the market in 2020, and is expected to continue this trend throughout the forecast period, owing to increasing prevalence rate of cerebral palsy and rise in the approval of anticonvulsant drugs from the U.S. Food and Drug Administration (FDA).
By disease type, the cerebral palsy treatment market is classified into spastic cerebral palsy, dyskinetic cerebral palsy, ataxic cerebral palsy, and mixed cerebral palsy. The spastic cerebral palsy segment dominated the market in 2020, and is expected to continue this trend throughout the forecast period, as 80% of the total cerebral palsy patients are suffering from spastic cerebral palsy.
Depending on distribution channel, the market is classified into hospital pharmacies, retail stores and pharmacy, and online providers. The retail stores and pharmacy segment dominated the market in 2020, and is expected to continue this trend throughout the forecast period, owing to recent upgrades in the pharmaceutical sector, increase in expenses on the health & medicines, easy access to pharmaceuticals for general population, rise in awareness for cerebral palsy disorders, thereby encouraging treatments, which boost health insurance penetration.
North America accounted for a majority of the global cerebral palsy treatment market share in 2020, and is anticipated to remain dominant during the forecast period. This is attributed to significant rise in investments as well as partnerships and collaborations.
The key players in this market have adopted product launch as one of their key developmental strategies such as acquisitions and partnerships. The major companies profiled in the report include Merz Pharmaceuticals, LLC., Pfizer, Inc., Teva Pharmaceuticals, Bayer AG, Johnson and Johnson, GSK, Novartis, Abbvie, Par Pharmaceuticals and LAnnett Company.
Key Findings Of The Study
- By drug type, the anticonvulsants segment was the highest contributor to the market in 2020 and is expected to continue during the forecast period owing to increasing prevalence rate of cerebral palsy, and rise in the approval of anticonvulsant drugs from the U.S Food and Drug Administration (FDA)
- By disease type, the spastic cerebral palsy segment dominated the global cerebral palsy treatment market in 2020, as around 80% of the total cerebral palsy patients are suffering from spastic cerebral palsy
- Based on distribution channel, the retail stores and pharmacy segment dominated the global market in 2020 and is anticipated to continue this trend during the forecast period owing to recent upgrades in the pharmaceutical sector, increase in expenses on the health & medicines, easy access to pharmaceuticals for the general population, rise in awareness for cerebral palsy disorders thereby encouraging the treatments, and boost in the health insurance penetration
- On the basis of region, in 2020, North America dominated the market in 2020, owing to significant rise in investments as well as partnerships and collaborations
Companies Mentioned
- Merz Pharmaceuticals, LLC.
- Pfizer Inc.
- Teva Pharmaceuticals
- Bayer AG
- Johnson & Johnson
- GlaxoSmithKline plc.
- Novartis, AbbVie Inc.
- Par Pharmaceutical
- Allergan plc.
- Lannett Company, Inc.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 274 |
Published | February 2022 |
Forecast Period | 2020 - 2030 |
Estimated Market Value ( USD | $ 3166.82 million |
Forecasted Market Value ( USD | $ 4365.01 million |
Compound Annual Growth Rate | 3.3% |
Regions Covered | Global |
No. of Companies Mentioned | 10 |